Follow-up of relapsed B-cell lymphoma patients treated with iodine-131- labeled anti-CD20 antibody and autologous stem-cell rescue

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3270-3278

  Liu, Steven Y ^a   Eary, Janet F ^a   Petersdorf, Stephen H ^a   Martin, Paul J ^a   Maloney, David G ^a   Appelbaum, Frederick R ^a   Matthews, Dana C ^a   Bush, Sharon A ^a   Durack, Lawrence D ^a   Fisher, Darrell R ^a   Gooley, Theodore A ^a   Bernstein, Irwin D ^a   Press, Oliver W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 20; UNCLASSIFIED DRUG;

ADULT; ANTIBODY LABELING; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL ARTICLE; DOSIMETRY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNE RESPONSE; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TUMOR LOCALIZATION;

EID: 0031759838     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3270     Document Type: Article

References (48)

1. Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl J Med 328:1023-1030, 1993
2. Philip T, Armitage JO, Spitzer G, et al: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade, non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498, 1987
3. Appelbaum FR, Sullivan KM, Buckner CD, et al: Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 5:1340-1347, 1987
4. Fisher RI, Stiff PJ: Treatment options for recurrent lymphomas. Semin Oncol 17:60-73, 1990 (suppl 4)
5. Horning SJ, Negrin RS, Chao NC, et al: Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 12:2552-2558,1994
6. Bearman SI, Appelbaum FR, Buckner CD, et al: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562-1568, 1988
7. Benyunes MC, Sullivan KM, Deeg HJ, et al: Cataracts after bone marrow transplantation: Long-term follow-up of adults treated with fractionated total body irradiation. Int J Radiat Oncol Biol Phys 32:661-670, 1995
8. Belkacemi Y, Ozsahin M, Pene F, et al: Cataractogenesis after total body irradiation. Int J Radiat Oncol Biol Phys 35:53-60, 1996
9. Boulad F, Bromley M, Black P, et al: Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. Bone Marrow Transplant 15:71-76, 1995
10. Stone RM: Myelodysplastic syndrome after autologous transplantation for lymphoma: The price of progress? Blood 83:3437-3440, 1994 (editorial)
11. Miller JS, Arthur DC, Litz CE, et al: Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy. Blood 83:3780-3786, 1994
12. Bhatia S, Ramsay NK, Steinbuch M, et al: Malignant neoplasms following bone marrow transplantation. Blood 87:3633-3639, 1996
13. Curtis RE, Rowlings PA, Deeg HJ, et al: Solid cancers after bone marrow transplantation. N Engl J Med 336:897-904, 1997
14. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993
15. 131 I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995
16. Eary JF, Press OW, Badger CC, et al: Imaging and treatment of B-cell lymphoma. J Nucl Med 31:1257-1268, 1990
17. Eary JF, Appelbaum F, Durack LD, et al: Preliminary validation of the opposing view method for quantitative gamma camera imaging. Med Phys 16:382-387,1989
18. Loevinger R, Budinger TF, Watson EE: MIRD Primer for Absorbed Dose Calculation, revised ed. New York, NY, Society of Nuclear Medicine, 1991
19. Fisher DR, Badger CC, Breitz H, et al: Internal radiation dosimetry for clinical testing of radiolabeled monoclonal antibodies. Antibodies Immunoconjugates Radiopharm 4:655-664, 1991
20. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswold meeting. J Clin Oncol 7:1630-1636, 1989 (erratum, 8:1602, 1990)
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
22. Pepe MS, Longton G, Pettinger M, et al: Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: Motivation for and description of new methods. Br J Haematol 83:602-607, 1993
23. Goldenberg DM, Horowitz J, Sharkey RM, et al: Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9:548-564, 1991
24. Juweid M, Sharkey RM, Markowitz A, et al: Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 55:5899S-5907S, 1995
25. Lewis JP, DeNardo GL, DeNardo SJ: Radioimmunotherapy of lymphomas: A UC Davis experience. Hybridoma 14:115-120, 1995
26. Kaminski MS, Fig LM, Zasadny KR, et al: Imaging, dosimetry and radioimmunotherapy with iodine-131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 10:1696-1711, 1992
27. Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981, 1996
28. Knox SJ, Goris ML, Trisler K, et al: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457-470, 1996
29. Rosen ST, Zimmer AM, Goldman-Leikin R, et al: Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131-I-labeled monoclonal antibody: An Illinois Cancer Council study. J Clin Oncol 5:562-573, 1987
30. DeNardo SJ, DeNardo GL, O'Grady LF, et al: Treatment of B cell malignancies with 131-1 Lym-1 monoclonal antibodies. Int J Cancer 3:96-101, 1988(suppl)
31. Johnson PW, Rohatiner AZ, Whelan JS, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 13:140-147, 1995
32. Press OW, Livingston R, Mortimer J, et al: Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 9:423-431, 1991
33. Velasquez WS, McLaughlin P, Tucker S, et al: ESHAP - An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 12:1169-1176, 1994
34. Rodriguez MA, Cabanillas FC, Velasquez W, et al: Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13:1734-1741, 1995
35. Wilson WH, Bryant G, Bates S, et al: EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11:1573-1582, 1993
36. Freedman AS, Ritz J, Neuberg D, et al: Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 77:2524-2529, 1991
37. Rohatiner AZS, Johnson PWM, Price CGA, et al: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12:1177-1184, 1994
38. Bastion Y, Brice P, Haioun C, et al: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 86:3257-3262, 1995
39. Bierman PJ, Vose JM, Anderson JR, et al: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450, 1997
40. Freedman A, Gribben J, Neuberg D, et al: Long-term prolongation of disease-free and overall survival following autologous bone marrow transplantation in patients with advanced relapsed follicular lymphoma. Proc Am Soc Clin Oncol 16:90a, 1997 (abstr 314)
41. Lindsay S, Chaikoff I: The effects of irradiation of the thyroid gland with particular reference to the induction of thyroid neoplasia. Cancer Res 24:1099-1107, 1964
42. Hancock SL, Cox RS, McDougall IR: Thyroid diseases after the treatment of Hodgkin's disease. N Engl J Med 325:599-605, 1991
43. Franklyn JA: The management of hyperthyroidism. N Engl J Med 330:1731-1738, 1994
44. Kendall-Taylor P, Keir MJ, Ross WM: Ablative radioiodine therapy for hyperthyroidism: long term follow up study. Br Med J 289:361-363, 1984
45. Dobyns BM, Sheline GE, Workman JB, et al: Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: A report of the cooperative thyrotoxicosis therapy follow up study. J Clin Endocrinol Metab 38:976-998, 1974
46. Hall P, Holm LE: Late consequences of radioiodine for diagnosis and therapy in Sweden. Thyroid 7:205-208, 1997
47. Paganelli G, Pervez S, Siccardi AG, et al: Intraperitoneal radio-localization of tumors pretargeted by biotinylated monoclonal antibodies. Int J Cancer 45:1184, 1990
48. Sung C, van Osdol WW: Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidinbiotin binding. J Nucl Med 36:867-876, 1995